Cayman CYY292

CYY292 is an inhibitor of PDGFRα, PDGFRβ, FGFR1, -2, and -3, (IC₅₀s = 5.35, 4.6, 28, 28, and 78 nM, respectively).^1,2 It is selective for these kinases over FGFR4 (IC₅₀ = >1,000 nM) but also inhibits c-Kit, VEGFR2, VEGFR1, and insulin-like growth factor 1 receptor (IGF-1R; IC₅₀s = 67, 33, 36, and 75 nM, respectively), as well as EGFR, Bruton’s tyrosine kinase (BTK), cyclin-dependent kinase 4 (Cdk4)/cyclin D3, and MET (IC₅₀s = 128, 198, 214, and 396 nM, respectively).² CYY292 inhibits the proliferation of mg-63, U2OS, MNNG/HOS, and Saos-2 osteosarcoma cells (IC₅₀s = 0.84, 0.76, 1.36, and 0.72 µM, respectively).¹ It inhibits the migration and invasion of U87MG and LN-229 glioblastoma cells when used at concentrations of 0.3 and 0.5 µM.² CYY292 (30 mg/kg) decreases tumor volume and increases survival in a U87MG orthotopic mouse xenograft model.

WARNING This product is not for human or veterinary use.